米氮平与舍曲林治疗抑郁症伴有焦虑的临床对比观察

Clinical comparative observation of mirtazapine and sertraline in the treatment of depression with anxiety

目的探讨米氮平与舍曲林治疗抑郁症伴有焦虑患者的临床疗效及安全性。方法选择我院治疗的抑郁症伴有焦虑患者96例,根据治疗方法不同分为对照组,每组各48例,对照组给予舍曲林治疗,观察组给予米氮平治疗,观察两组治疗效果。结果两组抗抑郁治疗效果比较,差异无统计学意义(P>0.05)。观察组抗焦虑治疗效果优于对照组,差异有统计学意义(P<0.05)。观察组在治疗1周后汉密尔顿焦虑量表和抑郁量表评分降低程度优于对照组,差异有统计学意义(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论米氮平治疗抑郁症与舍曲林疗效相当,但是其抗焦虑效果优于对照组,且起效较快,不良反应可以耐受,值得在临床上大力推广使用。

Objective To investigate the clinical efficacy and safety of mirtazapine and sertraline in the treatment of patients of depression with anxiety. Methods 96 patients of depression with anxiety in our hospital were divided into two groups according to different treatment method, each group had 48 cases.The control group were received sertraline treatment, while the observation group were received mirtazapine treatment.The therapeutic effect of two groups were observed. Results There was no significant difference in antidepressant treatment effect between two groups（P 〈 0.05）. The anxiolytic treatment effect of the observation group was better than that of the control group,and the difference was statistically significant（P 〈 0.05）. The decreased level of Hamilton Anxiety Scale score and Depression Scale score after a week of treatment in the observation group were better than those in the control group,and the difference was statistically significant（P 〈 0.05）.There was no significant difference in incidence of adverse reactions between two groups（P 〈 0.05）. Conclusion The effect of mirtazapine in the treatment of depressive is equivalent to sertraline,but its anxiolytic effect is better than that of the control group,and it has more rapid onset,tolerated adverse reactions,and is worthy of clinical promotion and application.